Hims to cut 4% of workforce amid ban on weight-loss drug copies
Telehealth platform Hims & Hers will cut about 4% of its workforce, as it adjusts to a U.S. ban on manufacturing mass copies of the weight-loss drug Wegovy.
You are not logged in so some information on this page has been withheld. To see more, please log in.
Hers
since
auto-detected in 292 stories
4 days ago
30 days ago
Hims & Hers gives weak outlook but says more collaborations are coming
Hims & Hers shares fell in extended trading on Monday after the company reported first-quarter earnings that offered soft guidance.
Hims & Hers brings former Amazon executive into C-suite
Hims & Hers Health announced Nader Kabbani will join the telehealth company as its chief operations officer.
36 days ago
Novo Nordisk opens weight loss drug Wegovy to telehealth; Hims & Hers shares rocket 23%
Novo Nordisk is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy copycats, with rare exceptions.
Novo Nordisk opens weight loss drug Wegovy to telehealth; Hims & Hers shares rocket 23%
Novo Nordisk is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy copycats, with rare exceptions.
Stocks making the biggest moves midday: Spotify, Regeneron, Hims & Hers, Pfizer and more
These are the stocks posting the largest moves in midday trading.
Novo Nordisk opens weight loss drug Wegovy to telehealth; Hims & Hers shares rocket 18%
Novo Nordisk is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy copycats, with rare exceptions.
Novo Nordisk opens weight loss drug Wegovy to telehealth; Hims & Hers shares rocket 18%
Novo Nordisk is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy copycats, with rare exceptions.
Novo Nordisk opens weight loss drug Wegovy to telehealth; Hims & Hers shares rocket 18%
Novo Nordisk is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy copycats, with rare exceptions.
Novo Nordisk opens weight loss drug Wegovy to telehealth; Hims & Hers shares rocket 30%
Novo Nordisk is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy copycats, with rare exceptions.